Expanded Access to Tipifarnib

Available (expanded access)

Conditions studied: HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

In brief

Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.

Key facts

Study ID

NCT04809233

Run by

Kura Oncology, Inc.

Last updated by the study team

2026-06-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.